Brokerage firm Bank of America Upgrades its rating on Catalent Inc(NYSE:CTLT). The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by Bank of America was issued on Jun 20, 2016.
In a different note, On May 5, 2016, William Blair said it Downgrades its rating on Catalent Inc. The shares have been rated ‘Market Perform’ by the firm. On Apr 21, 2016, Morgan Stanley said it Downgrades its rating on Catalent Inc. The shares have been rated ‘Ewu’ by the firm.
Catalent Inc (CTLT) shares turned negative on Fridays trading session with the shares closing down -0.87 points or -3.68% at a volume of 27,96,287. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $23.2. The peak price level was also seen at $23.2 while the days lowest was $22.53. Finally the shares closed at $22.79. The 52-week high of the shares is $34.415 while the 52-week low is $18.92. According to the latest information available, the market cap of the company is $2,841 M.
Catalent Inc(CTLT) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $438.00M. Analysts had an estimated revenue of $427.73M. Earnings per share were $0.20. Analysts had estimated an EPS of $0.32.
Several Insider Transactions has been reported to the SEC. On Jun 1, 2016, Matthew M Walsh (officer ) sold 21,197 shares at $28.85 per share price.Also, On Aug 19, 2015, John R Chiminski (director officer ) sold 38,505 shares at $33.87 per share price.On Apr 3, 2015, Scott Houlton (officer ) sold 16,253 shares at $30.61 per share price, according to the Form-4 filing with the securities and exchange commission.
Catalent Inc. is a provider of advanced delivery technologies and development solutions for drugs biologics and consumer health products. The Company’s segments include Oral Technologies Medication Delivery Solutions and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies including formulation development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle. The Medication Delivery Solutions segment provides formulation development and manufacturing services for delivery of drugs and biologics administered through injection inhalation and ophthalmic routes using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing packaging storage and inventory management for drugs and biologics in clinical trials.